Henry Schein, Inc. (NASDAQ:HSIC) has been assigned an average rating of “Hold” from the twenty research firms that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $74.03.
Several equities analysts recently weighed in on the company. Zacks Investment Research downgraded Henry Schein from a “buy” rating to a “hold” rating and set a $76.00 price objective for the company. in a research note on Wednesday, June 19th. William Blair cut Henry Schein from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 7th. TheStreet cut Henry Schein from a “b” rating to a “c+” rating in a report on Friday, August 30th. BidaskClub cut Henry Schein from a “hold” rating to a “sell” rating in a report on Thursday, September 26th. Finally, Barrington Research reiterated a “buy” rating and set a $75.00 target price on shares of Henry Schein in a report on Wednesday, August 7th.
NASDAQ HSIC traded up $1.11 during mid-day trading on Friday, hitting $63.49. The stock had a trading volume of 3,325 shares, compared to its average volume of 1,008,790. Henry Schein has a 52-week low of $56.58 and a 52-week high of $72.81. The company has a market cap of $9.21 billion, a price-to-earnings ratio of 15.40, a P/E/G ratio of 2.40 and a beta of 0.86. The company has a 50 day simple moving average of $62.17 and a 200 day simple moving average of $64.95. The company has a quick ratio of 0.95, a current ratio of 1.70 and a debt-to-equity ratio of 0.33.
In other news, Vice Chairman James P. Breslawski sold 6,856 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $60.17, for a total transaction of $412,525.52. Following the sale, the insider now owns 249,046 shares in the company, valued at $14,985,097.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.06% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of the company. Bridge Creek Capital Management LLC boosted its holdings in shares of Henry Schein by 1.5% during the third quarter. Bridge Creek Capital Management LLC now owns 39,904 shares of the company’s stock worth $2,534,000 after purchasing an additional 582 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Henry Schein by 11.9% in the 3rd quarter. Pacer Advisors Inc. now owns 30,427 shares of the company’s stock worth $1,932,000 after buying an additional 3,224 shares during the period. State of Alaska Department of Revenue raised its position in shares of Henry Schein by 109.8% in the 3rd quarter. State of Alaska Department of Revenue now owns 83,332 shares of the company’s stock worth $5,290,000 after buying an additional 43,621 shares during the period. Macquarie Group Ltd. raised its position in shares of Henry Schein by 29.4% in the 2nd quarter. Macquarie Group Ltd. now owns 4,847 shares of the company’s stock worth $339,000 after buying an additional 1,100 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in shares of Henry Schein by 231.8% in the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 137,844 shares of the company’s stock worth $9,635,000 after buying an additional 96,295 shares during the period.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.